1. Phylogeny  
   Serine/threonine‐protein kinase A‑Raf (A‑Raf) is a member of the Raf kinase family, a group of evolutionarily conserved mitogen‐activated protein kinase kinase kinases (MAP3Ks) within the serine/threonine kinase superfamily. A‑Raf is grouped together with its paralogs B‑Raf and C‑Raf, all of which share a common origin and display a conserved domain structure that includes an N‑terminal regulatory region with a Ras‑binding domain (RBD) and cysteine‑rich domain (CRD) as well as a C‑terminal catalytic kinase domain. Phylogenetic analyses based on comparisons of catalytic domain sequences reveal that the RAF family has been maintained from yeast to mammals and that gene duplication events in early metazoans gave rise to the three isoforms found in vertebrates today (beeram2005rafastrategic pages 4-6, champion2004arabidopsiskinomeafter pages 14-15). In addition, studies of the interplay of RAF kinases with other proteins in the MAPK pathway have further confirmed that A‑Raf, like its paralogs, belongs to the CMGC group of kinases and is embedded within an evolutionary core set of MAP3Ks that mediate Ras‑dependent signaling (gan2013differentrafprotein pages 2-3, degirmenci2020targetingaberrantrasrafmekerk pages 20-21). Comparative structural assessments also indicate that conserved motifs within the RBD and kinase domain serve as strong phylogenetic markers; thus, A‑Raf shares many of the regulatory and catalytic features that define the Raf subfamily (simanshu2022astructureis pages 5-6, bahar2023targetingtherasrafmapk pages 5-6).
2. Reaction Catalyzed  
   A‑Raf catalyzes the transfer of a phosphate group from adenosine triphosphate (ATP) to the hydroxyl group of serine or threonine residues on substrate proteins. The overall chemical reaction follows the general kinase mechanism:  
     ATP + [protein]‑(L‑serine or L‑threonine) → ADP + [protein]‑(L‑serine/threonine)‑phosphate + H⁺  
   This phosphorylation reaction is central to its function in transducing mitogenic signals from the cell membrane to the nucleus (beeram2005rafastrategic pages 4-6).
3. Cofactor Requirements  
   Like many serine/threonine kinases, the catalytic activity of A‑Raf is dependent on the presence of divalent magnesium ions (Mg²⁺). Mg²⁺ serves as a cofactor by coordinating the binding of ATP within the active site and facilitating the phosphotransfer reaction (beeram2005rafastrategic pages 4-6, degirmenci2020targetingaberrantrasrafmekerk pages 20-21).
4. Substrate Specificity  
   A‑Raf phosphorylates serine/threonine residues on specific substrates downstream in the MAPK cascade. Although its substrate specificity is not as comprehensively characterized as that of some other kinases, A‑Raf is well known to phosphorylate the dual‐specificity kinases MEK1/2, serving as a critical link in the Ras‑ERK signaling pathway. In addition to MEK, A‑Raf has been reported to phosphorylate phosphofructokinase-2/fructose-2,6-bisphosphatase (PFKFB2), thereby potentially linking mitogenic signaling with metabolic regulation. The precise consensus sequence recognized by A‑Raf has not been as clearly defined as the RxRxxp[ST] motif recognized by some AGC kinases; however, its substrate interactions are mediated by the structural determinants within its catalytic domain and associated regulatory regions (gan2013differentrafprotein pages 2-3, degirmenci2020targetingaberrantrasrafmekerk pages 20-21, bahar2023targetingtherasrafmapk pages 6-7).
5. Structure  
   A‑Raf displays a modular architecture typical of the Raf kinase family. Its structure can be divided into two principal regions. The N‑terminal regulatory region is composed of the Ras‑binding domain (RBD), which facilitates interaction with GTP‑bound Ras, and the cysteine‑rich domain (CRD), which contributes to lipid binding and membrane association. These elements are essential for the receptor–effector coupling that allows A‑Raf to be recruited to activated Ras on the plasma membrane (gan2013differentrafprotein pages 2-3, bahar2023targetingtherasrafmapk pages 5-6).  
   The C‑terminal catalytic domain (CR3) adopts a bilobal structure characterized by a smaller N‑lobe consisting primarily of antiparallel β‑strands and a larger C‑lobe predominantly made up of α‑helices. Key catalytic features include the activation loop, crucial for substrate binding and catalytic efficiency; the αC‑helix, which plays a role in aligning essential residues within the active site; and the hydrophobic spine, a series of aligned nonpolar residues that stabilize the active conformation. Structural studies—based on high-resolution cryo-electron microscopy and comparative modeling with other RAF isoforms—indicate that A‑Raf likely forms dynamic conformational states governed by intramolecular interactions between its regulatory and kinase domains. These interactions are modulated by phosphorylation events and 14-3-3 protein binding, which can lock the kinase in either an inactive or active conformation, thereby affecting both its localization and catalytic activity (simanshu2022astructureis pages 5-6, terrell2019rasmediatedactivationof pages 2-4, bahar2023targetingtherasrafmapk pages 6-7).
6. Regulation  
   A‑Raf is regulated by an array of post‑translational modifications and protein–protein interactions that control its kinase activity and subcellular localization. Phosphorylation is a major regulatory mechanism; specific serine and threonine residues within the activation loop and the adjacent regulatory regions undergo phosphorylation in response to upstream signals. Such modifications facilitate the conformational shift from an autoinhibited state to an active state that is competent for substrate phosphorylation (an2015raf‐interactomeintuning pages 3-4, beeram2005rafastrategic pages 4-6).  
   Furthermore, A‑Raf is subject to regulation via binding of 14‑3‑3 proteins, which interact with phosphorylated motifs located within both the N‑terminal regulatory region and the C‑terminal tail. This binding not only stabilizes the inactive conformation under basal conditions but also modulates the transition to an active state upon mitogenic stimulation. Additionally, A‑Raf’s activity is influenced by its interactions with other signaling molecules such as Ras GTPases, which promote its membrane recruitment and subsequent activation, as well as with kinases including casein kinase 2 (CK2) and members of the Src family, which further modify key regulatory phosphorylation sites (rauch2019spatialregulationof pages 1-2, bahar2023targetingtherasrafmapk pages 6-7, degirmenci2020targetingaberrantrasrafmekerk pages 20-21).
7. Function  
   A‑Raf plays a vital role in the transduction of mitogenic signals from the cell surface to the nucleus. Once activated by binding to GTP‑loaded Ras, A‑Raf phosphorylates downstream effectors—most notably the dual‑specificity kinases MEK1/2—thereby initiating the Ras‑Raf‑MEK‑ERK signaling cascade that controls cell proliferation, differentiation, and survival. In addition to its canonical role in MAPK signaling, A‑Raf has been implicated in the regulation of metabolic pathways through phosphorylation of substrates such as phosphofructokinase B‑2 (PFKFB2) and in the modulation of the target of rapamycin (TOR) signaling cascade (an2015raf‐interactomeintuning pages 3-4, gan2013differentrafprotein pages 2-3). Expression studies have demonstrated that A‑Raf is present in multiple tissues, where it contributes to cellular responses to growth factors and other mitogenic stimuli, and it participates in protein complexes that ensure proper signal propagation through the MAPK pathway (champion2004arabidopsiskinomeafter pages 7-9, bahar2023targetingtherasrafmapk pages 6-7).
8. Other Comments  
   In the context of therapeutic targeting, inhibitors designed to disrupt the Ras/RAF/MEK/ERK pathway have been developed, with some compounds showing efficacy in cancers driven by aberrant Ras signaling. Although A‑Raf is generally considered less frequently mutated than B‑Raf, alterations in its expression or regulatory mechanisms have been reported in various malignancies, where they may contribute to oncogenic signaling through both kinase-dependent and kinase-independent mechanisms (beeram2005rafastrategic pages 6-7, degirmenci2020targetingaberrantrasrafmekerk pages 20-21). Additionally, A‑Raf’s involvement in both mitogenic and metabolic regulation positions it as a potential link between proliferative signaling and cellular energy homeostasis. The development of selective inhibitors remains an active area of investigation, particularly for indications in which dysregulated Raf signaling plays an integral role (bahar2023targetingtherasrafmapk pages 6-7).
9. References
10. an2015raf‐interactomeintuning pages 3-4
11. beeram2005rafastrategic pages 4-6
12. champion2004arabidopsiskinomeafter pages 14-15
13. gan2013differentrafprotein pages 2-3
14. mohanty2016hydrophobiccorevariations pages 4-5
15. rauch2019spatialregulationof pages 1-2
16. simanshu2022astructureis pages 5-6
17. terrell2019rasmediatedactivationof pages 2-4
18. bahar2023targetingtherasrafmapk pages 5-6
19. bahar2023targetingtherasrafmapk pages 6-7
20. degirmenci2020targetingaberrantrasrafmekerk pages 20-21

References

1. (an2015raf‐interactomeintuning pages 3-4): Su An, Yang Yang, Richard Ward, Ying Liu, Xiao‐Xi Guo, and Tian‐Rui Xu. Raf‐interactome in tuning the complexity and diversity of raf function. The FEBS Journal, Jan 2015. URL: https://doi.org/10.1111/febs.13113, doi:10.1111/febs.13113. This article has 25 citations.
2. (beeram2005rafastrategic pages 4-6): Muralidhar Beeram, Amita Patnaik, and Eric K. Rowinsky. Raf: a strategic target for therapeutic development against cancer. Journal of Clinical Oncology, 23:6771-6790, Sep 2005. URL: https://doi.org/10.1200/jco.2005.08.036, doi:10.1200/jco.2005.08.036. This article has 386 citations and is from a highest quality peer-reviewed journal.
3. (champion2004arabidopsiskinomeafter pages 7-9): A. Champion, M. Kreis, K. Mockaitis, K. Mockaitis, A. Picaud, and Y. Henry. Arabidopsis kinome: after the casting. Functional & Integrative Genomics, 4:163-187, Jan 2004. URL: https://doi.org/10.1007/s10142-003-0096-4, doi:10.1007/s10142-003-0096-4. This article has 158 citations.
4. (gan2013differentrafprotein pages 2-3): Xiaoqing Gan, Chen Wang, Maulik Patel, Barry Kreutz, Maggie Zhou, Tohru Kozasa, and Dianqing Wu. Different raf protein kinases mediate different signaling pathways to stimulate e3 ligase rffl gene expression in cell migration regulation. Journal of Biological Chemistry, 288:33978-33984, Nov 2013. URL: https://doi.org/10.1074/jbc.m113.477406, doi:10.1074/jbc.m113.477406. This article has 23 citations and is from a domain leading peer-reviewed journal.
5. (mohanty2016hydrophobiccorevariations pages 4-5): Smita Mohanty, Krishnadev Oruganty, Annie Kwon, Dominic P. Byrne, Samantha Ferries, Zheng Ruan, Laura E. Hanold, Samiksha Katiyar, Eileen J. Kennedy, Patrick A. Eyers, and Natarajan Kannan. Hydrophobic core variations provide a structural framework for tyrosine kinase evolution and functional specialization. PLOS Genetics, 12:e1005885, Feb 2016. URL: https://doi.org/10.1371/journal.pgen.1005885, doi:10.1371/journal.pgen.1005885. This article has 42 citations and is from a domain leading peer-reviewed journal.
6. (rauch2019spatialregulationof pages 1-2): Jens Rauch and Walter Kolch. Spatial regulation of araf controls the mst2-hippo pathway. Small GTPases, 10:1-6, Mar 2019. URL: https://doi.org/10.1080/21541248.2017.1288686, doi:10.1080/21541248.2017.1288686. This article has 11 citations and is from a peer-reviewed journal.
7. (simanshu2022astructureis pages 5-6): Dhirendra K. Simanshu and Deborah K. Morrison. A structure is worth a thousand words: new insights for ras and raf regulation. Cancer Discovery, 12:899-912, Jan 2022. URL: https://doi.org/10.1158/2159-8290.cd-21-1494, doi:10.1158/2159-8290.cd-21-1494. This article has 62 citations and is from a highest quality peer-reviewed journal.
8. (terrell2019rasmediatedactivationof pages 2-4): Elizabeth M. Terrell and D. Morrison. Ras-mediated activation of the raf family kinases. Cold Spring Harbor perspectives in medicine, 2019. URL: https://doi.org/10.1101/cshperspect.a033746, doi:10.1101/cshperspect.a033746. This article has 209 citations and is from a peer-reviewed journal.
9. (bahar2023targetingtherasrafmapk pages 5-6): Md Entaz Bahar, Hyun Joon Kim, and Deok Ryong Kim. Targeting the ras/raf/mapk pathway for cancer therapy: from mechanism to clinical studies. Signal Transduction and Targeted Therapy, Dec 2023. URL: https://doi.org/10.1038/s41392-023-01705-z, doi:10.1038/s41392-023-01705-z. This article has 388 citations and is from a peer-reviewed journal.
10. (bahar2023targetingtherasrafmapk pages 6-7): Md Entaz Bahar, Hyun Joon Kim, and Deok Ryong Kim. Targeting the ras/raf/mapk pathway for cancer therapy: from mechanism to clinical studies. Signal Transduction and Targeted Therapy, Dec 2023. URL: https://doi.org/10.1038/s41392-023-01705-z, doi:10.1038/s41392-023-01705-z. This article has 388 citations and is from a peer-reviewed journal.
11. (beeram2005rafastrategic pages 6-7): Muralidhar Beeram, Amita Patnaik, and Eric K. Rowinsky. Raf: a strategic target for therapeutic development against cancer. Journal of Clinical Oncology, 23:6771-6790, Sep 2005. URL: https://doi.org/10.1200/jco.2005.08.036, doi:10.1200/jco.2005.08.036. This article has 386 citations and is from a highest quality peer-reviewed journal.
12. (champion2004arabidopsiskinomeafter pages 14-15): A. Champion, M. Kreis, K. Mockaitis, K. Mockaitis, A. Picaud, and Y. Henry. Arabidopsis kinome: after the casting. Functional & Integrative Genomics, 4:163-187, Jan 2004. URL: https://doi.org/10.1007/s10142-003-0096-4, doi:10.1007/s10142-003-0096-4. This article has 158 citations.
13. (degirmenci2020targetingaberrantrasrafmekerk pages 20-21): Ufuk Degirmenci, Mei Wang, and Jiancheng Hu. Targeting aberrant ras/raf/mek/erk signaling for cancer therapy. Cells, 9:198, Jan 2020. URL: https://doi.org/10.3390/cells9010198, doi:10.3390/cells9010198. This article has 560 citations and is from a peer-reviewed journal.